IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of...
Clinical Trial
AI Could Add $461 Billion to Global Healthcare–And These New Platforms Are Leading the Charge
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 23, 2025 /PRNewswire/ -- Equity Insider...
CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer
Positive recommendation based on phase III INAVO120 data showing ItovebiTM (inavolisib) in combination with palbociclib and fulvestrant more than doubled...
Announcing the 2025 St. Baldrick’s Summer Fellows: Investing in the Future of Childhood Cancer Research
Los Angeles, California--(Newsfile Corp. - May 22, 2025) - The St. Baldrick's Foundation, the largest charity funder of childhood cancer...
Clymb Clinical Introduces TFL Viewer: A Cutting-Edge Platform for Collaborative Clinical Trial Reporting
BURLINGTON, Mass., May 22, 2025 /PRNewswire/ -- Clymb Clinical is proud to announce the launch of TFL Viewer, a state-of-the-art...
Neurostimulation Devices Market to Reach USD 17.2 Billion by 2031 – Driven by Demand for Pain and Parkinson’s Therapies | Valuates Reports
BANGALORE, India, May 22, 2025 /PRNewswire/ -- Neurostimulation Devices Market is Segmented by Type (Spinal Cord Stimulation (SCS), Gastric Electric...
Rodan + Fields Unveils “Love What You See” – A Campaign Honoring Personal Skincare Journeys
New purpose-driven brand campaign highlights the science behind R+F's skincare and the visible results it delivers at every stage of...
Xentria Launches Xturnpoint to Fuel Early-Stage Therapeutic Innovation, Expands Headquarters to Support Growth
Xentria introduces Xturnpoint, a venture partnering studio to support early-stage therapeutic innovators with an exclusive event on July 16, 2025...
Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
• BLA priority review of RP1 plus nivolumab in advanced melanoma proceeding on schedule; manufacturing inspections and late cycle review...
Sernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 Diabetes
LONDON, Ontario and BOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading...
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares
Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of acute gout flares Trial to...
Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
The Clinical Study Is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites...
AI In Healthcare Market Revenue worth $187.7 Billion by 2030 – Exclusive Study by The Research Insights
CHICAGO, May 21, 2025 /PRNewswire/ -- The global AI In Healthcare Market size is projected to be valued at USD 26.6 Billion in 2024...
Astellas and MBC BioLabs Announce the 2025 Astellas Future Innovator Prize Awarded to DeepSeq.AI & Serna Bio
Both companies have earned a year-long opportunity for access to a distinguished life-science incubator in San Francisco along with the...
Neurophet Participates ASNR 2025: Showcasing Clinical Utility of ‘Neurophet AQUA AD’
Co-CEO Jake Junkil Been joins Industry Collaboration Session to present Neurophet's brain imaging analysis technologies, including Neurophet AQUA ADCompany accelerates...
Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase
Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation GALWAY, Ireland, May...
Complement 1 Appoints Dr. Christopher Cogle as Chief Medical Officer to Lead Clinical Strategy for Innovative Cancer Lifestyle Platform
Renowned oncologist and translational researcher to spearhead medical strategy as company scales innovative lifestyle modification modelNEW YORK, May 21, 2025...
Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15
Study is expected to deliver final device data and documentation needed for planned FDA IND submissionSARASOTA, FL, May 21, 2025...
Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung Cancer
Silexion’s new groundbreaking study explores the potential impact of its next generation RNAI therapeutic candidate beyond pancreatic cancer aiming to...
ABLi Therapeutics Announces Details of the End of Phase 2 Meeting with FDA for Evaluation of Risvodetinib as a Treatment for Parkinson’s Disease
Agency supports primary and novel secondary and exploratory endpoints proposed for Phase 3 Trial(s) Opportunity to utilize time-to-delay of levodopa/carbidopa...